Background: Noonan syndrome is similar phenotypically to Turner syndrome, accounting for one in 1000-2500 live births. Two thirds of patients have cardiac anomalies, half with pulmonary stenosis. Two cases of Noonan syndrome in pregnancy are presented, each woman with a different cardiac anomaly.
Cases: The first patient sought preconception counseling for pulmonary stenosis. She conceived within a year and had a cesarean because of prolonged rupture of membranes, transverse lie, and variable decelerations. The second patient presented at 14 weeks' gestation with an unrepaired coarctation of the aorta. She had an assisted vaginal delivery at 38 weeks.
Conclusion: Successful pregnancy was possible in women with Noonan syndrome. A coordinated multidisciplinary team approach improved the likelihood of a successful outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0029-7844(98)00413-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beyond the postmortem diagnosis of HCM: a genetic approach guided by clinical and morphological features in Noonan syndrome.
Rev Esp Cardiol (Engl Ed)
January 2025
Cardiovascular Clinical Academic Group, St. George's University of London, St. George's University Hospitals NHS Foundation Trust, London, United Kingdom.
Endoscopic Mitral Surgery in Noonan Syndrome-Case Report and Considerations.
J Clin Med
January 2025
Department of Surgery IV, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 38 Gheorghe Marinescu Street, 540139 Targu Mures, Romania.
: Totally endoscopic techniques have become increasingly popular in cardiac surgery, with minimally invasive mitral valve repair emerging as an effective alternative to median sternotomy. This approach could be particularly advantageous for patients with Noonan syndrome, who often present with structural thoracic anomalies and other comorbidities like bleeding disorders. Endoscopic mitral valve surgery is rapidly establishing itself as the new standard of care for mitral valve operations, demonstrating both safety and efficacy.
View Article and Find Full Text PDFGH Therapy in Non-Growth Hormone-Deficient Children.
Children (Basel)
December 2024
Research Area for Innovative Therapy in Endocrinology, Bambino Gesù Children Hospital, IRCCS, 00165 Rome, Italy.
Before 1985, growth hormone (GH) was extracted from human pituitaries, and its therapeutic use was limited to children with severe GH deficiency (GHD). The availability of an unlimited amount of recombinant GH (rhGH) allowed for investigating the efficacy of its therapeutic use in a number of conditions other than GHD. Nowadays, patients with Turner syndrome, deficiency, Noonan syndrome, Prader-Willi syndrome, idiopathic short stature, chronic kidney disease, and children born small for gestational age can be treated with rhGH in order to improve adult height.
View Article and Find Full Text PDF[Growth and development patterns of Noonan syndrome and advances in the treatment of short stature].
Zhongguo Dang Dai Er Ke Za Zhi
January 2025
Department of Endocrinology, Metabolism and Genetics, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
Patients with Noonan syndrome (NS) are born with normal or slightly lower body length and weight compared to the normal ranges. However, their height gradually falls behind that of the general population, leading to growth retardation and delayed puberty. In China, the incidence of short stature in patients with NS is approximately 65%.
View Article and Find Full Text PDFLong-acting growth hormones: innovations in treatment and guidance on patient selection in pediatric growth hormone deficiency.
Ann Pediatr Endocrinol Metab
January 2025
Department of Medicine, Surgery and Health Science, University of Trieste, Trieste, Italy.
Long-acting growth hormones (LAGHs) represent a significant advancement in the treatment of pediatric growth hormone deficiency (GHD), offering an alternative to daily recombinant human growth hormone (rhGH) therapy. Traditional rhGH treatments, while effective, require daily injections, often leading to poor adherence due to the frequency of dosing, injection pain, and difficulties with storage and travel. In contrast, LAGHs, such as somatrogon, somapacitan, and lonapegsomatropin, are designed for once-weekly administration, improving patient compliance and quality of life.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!